TY - JOUR A1 - Majounie, Elisa A1 - Renton, Alan E. A1 - Mok, Kin A1 - Dopper, Elise G. P. A1 - Waite, Adrian A1 - Rollinson, Sara A1 - Chiò, Adriano A1 - Restagno, Gabriella A1 - Nicolaou, Nayia A1 - Simon-Sanchez, Javier A1 - van Swieten, John C. A1 - Abramzon, Yevgeniya A1 - Johnson, Janel O. A1 - Sendtner, Michael A1 - Pamphlett, Roger A1 - Orrell, Richard W. A1 - Mead, Simon A1 - Sidle, Katie C. A1 - Houlden, Henry A1 - Rohrer, Jonathan D. A1 - Morrison, Karen E. A1 - Pall, Hardev A1 - Talbot, Kevin A1 - Ansorge, Olaf A1 - Hernandez, Dena G. A1 - Arepalli, Sampath A1 - Sabatelli, Mario A1 - Mora, Gabriele A1 - Corbo, Massimo A1 - Giannini, Fabio A1 - Calvo, Andrea A1 - Englund, Elisabet A1 - Borghero, Giuseppe A1 - Floris, Gian Luca A1 - Remes, Anne M. A1 - Laaksovirta, Hannu A1 - McCluskey, Leo A1 - Trojanowski, John Q. A1 - Van Deerlin, Vivianna M. A1 - Schellenberg, Gerard D. A1 - Nalls, Michael A. A1 - Drory, Vivian E. A1 - Lu, Chin-Song A1 - Yeh, Tu-Hsueh A1 - Ishiura, Hiroyuki A1 - Takahashi, Yuji A1 - Tsuji, Shoji A1 - Le Ber, Isabelle A1 - Brice, Alexis A1 - Drepper, Carsten A1 - Williams, Nigel A1 - Kirby, Janine A1 - Shaw, Pamela A1 - Hardy, John A1 - Tienari, Pentti J. A1 - Heutink, Peter A1 - Morris, Huw R. A1 - Pickering-Brown, Stuart A1 - Traynor, Bryan J. T1 - Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study JF - The Lancet Neurology N2 - Background We aimed to accurately estimate the frequency of a hexanucleotide repeat expansion in C9orf72 that has been associated with a large proportion of cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Methods We screened 4448 patients diagnosed with ALS (El Escorial criteria) and 1425 patients with FTD (Lund-Manchester criteria) from 17 regions worldwide for the GGGGCC hexanucleotide expansion using a repeat-primed PCR assay. We assessed familial disease status on the basis of self-reported family history of similar neurodegenerative diseases at the time of sample collection. We compared haplotype data for 262 patients carrying the expansion with the known Finnish founder risk haplotype across the chromosomal locus. We calculated age-related penetrance using the Kaplan-Meier method with data for 603 individuals with the expansion. Findings In patients with sporadic ALS, we identified the repeat expansion in 236 (7·0%) of 3377 white individuals from the USA, Europe, and Australia, two (4·1%) of 49 black individuals from the USA, and six (8·3%) of 72 Hispanic individuals from the USA. The mutation was present in 217 (39·3%) of 552 white individuals with familial ALS from Europe and the USA. 59 (6·0%) of 981 white Europeans with sporadic FTD had the mutation, as did 99 (24·8%) of 400 white Europeans with familial FTD. Data for other ethnic groups were sparse, but we identified one Asian patient with familial ALS (from 20 assessed) and two with familial FTD (from three assessed) who carried the mutation. The mutation was not carried by the three Native Americans or 360 patients from Asia or the Pacific Islands with sporadic ALS who were tested, or by 41 Asian patients with sporadic FTD. All patients with the repeat expansion had (partly or fully) the founder haplotype, suggesting a one-off expansion occurring about 1500 years ago. The pathogenic expansion was non-penetrant in individuals younger than 35 years, 50% penetrant by 58 years, and almost fully penetrant by 80 years. Interpretation A common Mendelian genetic lesion in C9orf72 is implicated in many cases of sporadic and familial ALS and FTD. Testing for this pathogenic expansion should be considered in the management and genetic counselling of patients with these fatal neurodegenerative diseases. KW - DNA repeat expansion KW - C9orf72 KW - amyotrophic lateral sclerosis KW - frontotemporal dementia KW - cross-sectional studies Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-154644 VL - 11 SP - 323 EP - 330 ER - TY - JOUR A1 - Williams, Richard D. A1 - Chagtai, Tasnim A1 - Alcaide-German, Marisa A1 - Apps, John A1 - Wegert, Jenny A1 - Popov, Sergey A1 - Vujanic, Gordan A1 - Van Tinteren, Harm A1 - Van den Heuvel-Eibrink, Marry M A1 - Kool, Marcel A1 - De Kraker, Jan A1 - Gisselsson, David A1 - Graf, Norbert A1 - Gessler, Manfred A1 - Pritchard-Jones, Kathy T1 - Multiple mechanisms of MYCN dysregulation in Wilms tumour JF - Oncotarget N2 - Genomic gain of the proto-oncogene transcription factor gene MYCN is associated with poor prognosis in several childhood cancers. Here we present a comprehensive copy number analysis of MYCN in Wilms tumour (WT), demonstrating that gain of this gene is associated with anaplasia and with poorer relapse-free and overall survival, independent of histology. Using whole exome and gene-specific sequencing, together with methylation and expression profiling, we show that MYCN is targeted by other mechanisms, including a recurrent somatic mutation, P44L, and specific DNA hypomethylation events associated with MYCN overexpression in tumours with high risk histologies. We describe parallel evolution of genomic copy number gain and point mutation of MYCN in the contralateral tumours of a remarkable bilateral case in which independent contralateral mutations of TP53 also evolve over time. We report a second bilateral case in which MYCN gain is a germline aberration. Our results suggest a significant role for MYCN dysregulation in the molecular biology of Wilms tumour. We conclude that MYCN gain is prognostically significant, and suggest that the novel P44L somatic variant is likely to be an activating mutation. KW - integrative genomics viewer KW - oncogene amplification KW - sequencing data KW - gene KW - gain KW - copy number KW - somatic mutations KW - beta-catenin KW - histology KW - reveals KW - Wilms tumour KW - MYCN KW - DNA methylation KW - prognostic marker Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-143471 VL - 6 IS - 9 ER -